Oncology
Extensive Stage Lung Small Cell Carcinoma
4
Pipeline Programs↗
3
Active Trials↗
4
Companies Involved↗
Extensive Stage Lung Small Cell Carcinoma is an early-stage landscape with 4 programs across 4 companies. The most active players are Merck & Co., Gynecologic Oncology Group, Amgen.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Preclinical1
Phase 1
No programs
Phase 3
No programs
Approved
No programs
Analysis
Modality Breakdown
4programs
Small molecule250%
Monoclonal antibody250%
Modality classified for 100% of 4 pipeline programs.
Analysis
Trial Status
3
clinical trials
Recruiting2 · 67%
Active, not recruiting1 · 33%
Clinical Trials
Trial Activity
A Front-Line Window-of-Opportunity Phase 2 Study of Tarlatamab (Bispecific T Cell Engager: DLL3-CD3) in Patients With Extensive-Stage Small-Cell Lung Cancer
Recruiting·—·Phase 2·NCT07423585·39 enrolled
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)